Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 32Leiomyoma 9Menorrhagia 5Prostate Adenocarcinoma 2Myofibroma 2Endometriosis 2Adenocarcinoma 2Pathologic Complete Response 1Neoplasm, Residual 1Neoplasm Metastasis 1Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1Metastatic Castration-Resistant Prostate Cancer 1Hormone Treatment-naïve Participants With Prostate Cancer 1

Interventions

Oxaliplatin 46Gemcitabine 45Fluorouracil 40Capecitabine 31pembrolizumab 29Leucovorin 29Docetaxel 27Cisplatin 25Paclitaxel 23Irinotecan 18Carboplatin 18Bevacizumab 18130-nm albumin-bound paclitaxel 17Pemetrexed 15Albumin-Bound Paclitaxel 15Radiotherapy 14Nivolumab 12Ramucirumab 11Cyclophosphamide 11Trastuzumab 8Erlotinib Hydrochloride 8Taxes 7Radiosurgery 7Drug Therapy 7cemiplimab 6zolbetuximab 5trastuzumab deruxtecan 5regorafenib 5durvalumab 5Sorafenib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Adenocarcinoma × relugolix × Clear all
NCT06631521 2026-02-05

Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer

AdventHealth

Phase 1 Recruiting
30 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT07302451 2026-01-06

REDI-CaP

National Cancer Institute, Naples

Phase 2 Active not recruiting
50 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡